THURSDAY, Sept. 28, 2023 (HealthDay News) – An advisory panel to the U.S. Food and Drug Administration on Wednesday voted resoundingly against recommending a stem cell-based experimental treatment for ALS. Although the FDA isn’t bound by the votes of its advisory panels, agency scientists have already penned a scathing review of the drug, called NuOwn.… read on > read on >







